

**AMENDMENTS TO THE CLAIMS**

A marked-up version of the claims that will be pending following entry of the present amendments showing the amendments made herein follows. Matter that has been deleted from the claims is indicated by strikethrough and matter that has been added is indicated by underlining.

1.-24. (Cancelled)

25. (Once Amended) A method of treating ischemia reperfusion injury, comprising administering at least one of alpha1-antitrypsin, alpha1-antitrypsin-like agent, antielastase, or antiproteinase-3 agent, ~~or a serine protease inhibitor~~  
(benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl)carbonyl-2-(5)-methylpropyl]-L-prolinamide, or a combination thereof, and a therapeutically effective amount of at least one free radical scavenger, wherein the at least one free radical scavenger is 2,6,8-trihydroxypurine, dihydrorhodamine, or a combination thereof.

26. (Original) The method of claim 25, additionally comprising administering a thrombolytic agent.

27. (Original) The method of claim 25, additionally comprising using a mechanical device to reestablish blood flow.

28. (Original) The method of claim 25, wherein the ischemia reperfusion injury is associated with at least one of heart, brain, lung, kidneys or liver.

29. (Original) The method of claim 25, wherein the alpha1-antitrypsin-like agent is a form of alpha1-antitrypsin resistant to inactivation by oxygen reactive intermediates.

30. (Original) The method of claim 27, wherein the mechanical device involves percutaneous transluminal coronary angioplasty or angioplasty.

31-36 (Canceled)